Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

BACKGROUND: The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint provides a survival advantage in patients with advanced disease. As a single agent,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Satoshi, Jackson, Christopher M, Yoshimura, Kiyoshi, Yen, Hung-Rong, Getnet, Derese, Harris, Timothy J, Goldberg, Monica V, Bruno, Tullia C, Grosso, Joseph F, Durham, Nicholas, Netto, George J, Pardoll, Drew M, Drake, Charles G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666941/
https://www.ncbi.nlm.nih.gov/pubmed/23557194
http://dx.doi.org/10.1186/1479-5876-11-89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666941/
https://www.ncbi.nlm.nih.gov/pubmed/23557194
http://dx.doi.org/10.1186/1479-5876-11-89

Ejemplares similares